Label Changes for:

Zonegran (zonisamide) Capsules

January 2012

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) 

 

January 2012

ADVERSE REACTIONS

Postmarketing Experience
  • Acute pancreatitis, rhabdomyolysis, creatine phosphokinase increased
     

 

 

April 2010 

 

WARNINGS

Metabolic Acidosis
  • added safety-related language regarding metabolic acidosis

PRECAUTIONS

Kidney Stones
  • Although the clinical significance of the sonographic findings may not be certain, the development of nephrolithiasis may be related to metabolic acidosis.
Information for patients
  • Patients should contact their physician immediately if they develop fast breathing, fatigue/tiredness loss of appetite, or irregular heart beat or palpitations (possible manifestations of metabolic acidosis).

 

Hide
(web3)